|
|
|
| |
| Company Profile |
| |
|
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products in the areas of nephrology, supportive cancer care, and inflammatory disease. Its products primarily include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL, which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. EPOGEN and Aranesp stimulate the production of red blood cells to treat anemia. Neulasta and NEUPOGEN selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections. ENBREL blocks the biologic activity of tumor necrosis factor (TNF) by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. It sells its products to healthcare providers, including clinics, hospitals, and pharmacies primarily in the United States, Europe, Canada, and Australia. Amgen was established by Bill Bowes, Franklin Johnson, Sam Wohlsteadter, and Raymond Baddour in 1980. The company is headquartered in Thousand Oaks, California.
|
AMGEN Related |
|
Amgen Develops therapeutics in the areas of metabolism/nephrology, oncology, inflammation and bone diseases, and neurology.
|
|
Amgen - Careers Amgen, a biotechnology pioneer, discovers, develops and delivers innovative human therapeutics. ... Together, we live the Amgen values as we continue advancing ...
|
|
Amgen - Wikipedia, the free encyclopedia Kirin-Amgen v Hoechst Marion Roussel, a UK patent case decided by the House of Lords ... Amgen Inc. Company Profile Profile at Google Finance. ...
|
|
